New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
08:54 EDTEPZM, CELGEpizyme payment from Celgene suggests data positive, says JMP Securities
JMP Securities believes that the $25M proof of concept payment that Epizyme (EPZM) received from Celgene (CELG) suggests that the fourth dose cohort in the Phase I dose escalation study of Epizyme's EPZ-5676 yielded positive results. The firm reiterates a $40 price target and Outperform rating on Epizyme.
News For EPZM;CELG From The Last 14 Days
Check below for free stories on EPZM;CELG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
08:05 EDTEPZMEpizyme names Peter Ho as Chief Development Officer
Epizyme announced the appointments of Peter Ho, M.D., Ph.D., as Chief Development Officer and Michael Shih, J.D. as Vice President, Business Development. Ho will lead Epizyme’s clinical development, regulatory and translational medicine functions. Shih will lead Epizyme’s partnership strategy and execution.
07:27 EDTCELGIBC Life Sciences to hold a conference
Subscribe for More Information
September 12, 2014
10:00 EDTEPZMOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:27 EDTEPZMEpizyme initiated with a Buy at Mizuho
Target $35.
September 9, 2014
07:51 EDTCELGNICE says Abraxane price not justified by limited benefit in pancreatic cancer
Subscribe for More Information
September 8, 2014
07:26 EDTCELGMorgan Stanley to hold a conference
Subscribe for More Information
September 5, 2014
10:05 EDTCELGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) initiated with a Buy at ISI Group... Akamai (AKAM) initiated with a Buy at UBS... Alexion (ALXN) initiated with a Buy at SunTrust... Allegion (ALLE) initiated with a Buy at Buckingham... Allergan (AGN) initiated with a Buy at ISI Group... Aviat Networks (AVNW) initiated with a Neutral at H.C. Wainwright... Celgene (CELG) initiated with a Buy at SunTrust... EZCORP (EZPW) initiated with a Hold at Jefferies... Eaton (ETN) initiated with a Neutral at Buckingham... Emerson (EMR) initiated with a Neutral at Buckingham... HMS Holdings (HMSY) initiated with an Overweight at Stephens... Incyte (INCY) initiated with a Buy at SunTrust... Ingersoll-Rand (IR) initiated with a Neutral at Buckingham... Insmed (INSM) initiated with an Outperform at Cowen... Intercept (ICPT) initiated with an Outperform at Cowen... Johnson & Johnson (JNJ) initiated with an Outperform at BMO Capital... Lennox (LII) initiated with a Neutral at Buckingham... Mylan (MYL) initiated with a Hold at ISI Group... Orion Engineered Carbons (OEC) initiated with a Buy at Goldman... Parker-Hannifin (PH) initiated with a Buy at Buckingham... Pentair (PNR) initiated with a Neutral at Buckingham... Pharmacyclics (PCYC) initiated with a Neutral at SunTrust... Rockwell Automation (ROK) initiated with a Neutral at Buckingham... Sabre (SABR) initiated with an Outperform at Oppenheimer... Santander Consumer (SC) initiated with a Buy at Jefferies... Springleaf (LEAF) initiated with a Buy at Jefferies... Susser Petroleum (SUSP) initiated with a Neutral at Credit Suisse... Teva (TEVA) initiated with a Buy at ISI Group... Valeant (VRX) initiated with a Buy at ISI Group... WESCO (WCC) initiated with a Neutral at Buckingham... Watsco (WSO) initiated with a Neutral at Buckingham... Weyerhaeuser (WY) initiated with a Neutral at JPMorgan... World Acceptance (WRLD) initiated with a Hold at Jefferies.
September 4, 2014
17:56 EDTCELGCelgene initiated with a Buy at SunTrust
Target $121.
11:01 EDTEPZMEpizyme management to meet with Maxim
Cocktails and Group dinner to be held in New York on September 8 at 5:30 pm hosted by Maxim.
07:33 EDTCELGCelgene announces REVLIMID Phase III FIRST trial met primary endpoint
Subscribe for More Information
September 2, 2014
16:59 EDTEPZMEpizyme announces resignation of CFO
Subscribe for More Information
16:31 EDTEPZMEpizyme announces resignation of CFO Jason Rhodes and succession plan
Subscribe for More Information
09:41 EDTCELGActive equity options trading on open
Subscribe for More Information
08:19 EDTCELGCelgene GED301 drug has positive risk/reward ratio in near-term, says Bernstein
Bernstein believes that the upcoming trial of Celgene's GED0301 drug for Crohn's disease has very little risk in the near-term, while the presentation of results of a study of the drug next month should be positive for the stock. The firm thinks that the drug could emerge as a popular combination partner for other systemic drugs in patients who continue to have disease symptoms. Bernstein is more cautious about the drug's outlook starting in 2016 but keeps a $103 price target and Outperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use